Home > Publications Database > Added value of FDG-PET for detection of progressive supranuclear palsy. > print

001     280893
005     20250907001916.0
024 7 _ |a 10.1136/jnnp-2024-333590
|2 doi
024 7 _ |a pmid:39107038
|2 pmid
024 7 _ |a pmc:PMC12015049
|2 pmc
024 7 _ |a 0022-3050
|2 ISSN
024 7 _ |a 0266-8637
|2 ISSN
024 7 _ |a 0368-329X
|2 ISSN
024 7 _ |a 1468-330X
|2 ISSN
024 7 _ |a 2753-0477
|2 ISSN
024 7 _ |a 2753-0485
|2 ISSN
024 7 _ |a altmetric:166142000
|2 altmetric
037 _ _ |a DZNE-2025-00977
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Buchert, Ralph
|0 0000-0002-0945-0724
|b 0
245 _ _ |a Added value of FDG-PET for detection of progressive supranuclear palsy.
260 _ _ |a London
|c 2025
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756280749_29818
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Diagnostic criteria for progressive supranuclear palsy (PSP) include midbrain atrophy in MRI and hypometabolism in [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) as supportive features. Due to limited data regarding their relative and sequential value, there is no recommendation for an algorithm to combine both modalities to increase diagnostic accuracy. This study evaluated the added value of sequential imaging using state-of-the-art methods to analyse the images regarding PSP features.The retrospective study included 41 PSP patients, 21 with Richardson's syndrome (PSP-RS), 20 with variant PSP phenotypes (vPSP) and 46 sex- and age-matched healthy controls. A pretrained support vector machine (SVM) for the classification of atrophy profiles from automatic MRI volumetry was used to analyse T1w-MRI (output: MRI-SVM-PSP score). Covariance pattern analysis was applied to compute the expression of a predefined PSP-related pattern in FDG-PET (output: PET-PSPRP expression score).The area under the receiver operating characteristic curve for the detection of PSP did not differ between MRI-SVM-PSP and PET-PSPRP expression score (p≥0.63): about 0.90, 0.95 and 0.85 for detection of all PSP, PSP-RS and vPSP. The MRI-SVM-PSP score achieved about 13% higher specificity and about 15% lower sensitivity than the PET-PSPRP expression score. Decision tree models selected the MRI-SVM-PSP score for the first branching and the PET-PSPRP expression score for a second split of the subgroup with normal MRI-SVM-PSP score, both in the whole sample and when restricted to PSP-RS or vPSP.FDG-PET provides added value for PSP-suspected patients with normal/inconclusive T1w-MRI, regardless of PSP phenotype and the methods to analyse the images for PSP-typical features.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a IMAGE ANALYSIS
|2 Other
650 _ 7 |a MOVEMENT DISORDERS
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a PET
|2 Other
650 _ 7 |a SUPRANUCLEAR PALSY
|2 Other
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
650 _ 7 |a Radiopharmaceuticals
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnostic imaging
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Support Vector Machine
|2 MeSH
650 _ 2 |a Radiopharmaceuticals
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Atrophy
|2 MeSH
700 1 _ |a Huppertz, Hans-Jürgen
|0 0000-0003-3856-9094
|b 1
700 1 _ |a Wegner, Florian
|0 0000-0002-9931-2666
|b 2
700 1 _ |a Berding, Georg
|0 0000-0001-5592-8373
|b 3
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 4
|u dzne
700 1 _ |a Apostolova, Ivayla
|0 0000-0003-0290-7186
|b 5
700 1 _ |a Buhmann, Carsten
|0 0000-0001-8540-3789
|b 6
700 1 _ |a Poetter-Nerger, Monika
|0 0000-0001-7680-2147
|b 7
700 1 _ |a Dierks, Alexander
|b 8
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 9
700 1 _ |a Klietz, Martin
|0 0000-0002-3054-9905
|b 10
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 11
700 1 _ |a Mahmoudi, Nima
|0 0000-0002-2053-9623
|b 12
700 1 _ |a Rinscheid, Andreas
|0 0009-0008-8625-0217
|b 13
700 1 _ |a Quattrone, Andrea
|0 P:(DE-2719)9002627
|b 14
|u dzne
700 1 _ |a Rogozinski, Sophia
|b 15
700 1 _ |a Rumpf, Jost-Julian
|0 0000-0002-7357-713X
|b 16
700 1 _ |a Schneider, Christine
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Stöcklein, Sophia
|0 P:(DE-2719)9003671
|b 18
|u dzne
700 1 _ |a Spetsieris, Phoebe G
|0 0000-0001-7368-2354
|b 19
700 1 _ |a Eidelberg, David
|0 0000-0002-0854-864X
|b 20
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 21
|u dzne
700 1 _ |a Barthel, Henryk
|b 22
700 1 _ |a Wattjes, Mike P
|0 0000-0001-9298-2897
|b 23
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 24
|e Last author
700 1 _ |a Initiative, Alzheimer’s Disease Neuroimaging
|b 25
|e Collaboration Author
773 _ _ |a 10.1136/jnnp-2024-333590
|g Vol. 96, no. 3, p. 287 - 295
|0 PERI:(DE-600)1480429-3
|n 3
|p 287 - 295
|t Journal of neurology, neurosurgery, and psychiatry
|v 96
|y 2025
|x 0022-3050
856 4 _ |u https://pub.dzne.de/record/280893/files/DZNE-2025-00977%2BSUP.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/280893/files/DZNE-2025-00977%2BSUP.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280893
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001160
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 14
|6 P:(DE-2719)9002627
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 18
|6 P:(DE-2719)9003671
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)2814810
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J NEUROL NEUROSUR PS : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-28
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21